Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator

ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Rochester

About this trial

This prospective, multicenter, open-label, randomized-controlled trial compares two treatment strategies in high-risk ischemic cardiomyopathy (ICM) patients referred for primary ICD implantation. Participants will be randomized to receive either prophylactic VT ablation within three months of ICD implantation or continued medical management. The primary objective is to assess the efficacy of preventive VT ablation versus medical management in reducing VT arrhythmia burden.

Eligibility criteria

Qualifiers

Age ≥ 18 years (no upper age limit)

Willing and able to provide informed consent

Candidate for a primary prevention ICD/CRT-D per ESC guidelines17

Ischemic cardiomyopathy (ICM) with left ventricular ejection fraction (LVEF) ≤ 35%

Disqualifiers

Existing ICD or CRT-D

History of sustained VT or VF

Chronic renal failure requiring hemodialysis

Coronary revascularization within the past 3 months

Trial design

Treatments tested in this trial

  • Prophylactic Catheter-based VT Ablation

Treatment groups

62 Participants
are divided into 2 treatment groups

Sponsors and collaborators